Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on Mar ch 8 , Fool.com contributors Brian Orelli and Keith Speights discuss why Amgen needs to seek out this potential growth and whether Five Prime's pipeline is worth the premium Amgen paid for it.
For further details see:
Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?